Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University College, London
Hoffmann-La Roche
Hoffmann-La Roche
Incyte Corporation
Emory University
Trishula Therapeutics, Inc.
Gilead Sciences
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Celgene
Hutchmed
Gilead Sciences
Kyowa Kirin Co., Ltd.
Hoffmann-La Roche
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Dana-Farber Cancer Institute
Molecular Templates, Inc.
Takeda
CTI BioPharma
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Pfizer
Eli Lilly and Company
University of California, San Francisco
M.D. Anderson Cancer Center
CTI BioPharma
M.D. Anderson Cancer Center
Acrotech Biopharma Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Celgene
Fondazione Italiana Linfomi - ETS
Celgene
Northwestern University
Northwestern University
Pfizer
Merck Sharp & Dohme LLC
Takeda
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Stanford University
US Oncology Research
Progen Pharmaceuticals
University of Rochester
National Cancer Institute (NCI)
SWOG Cancer Research Network